Occult HBV infection

Seminars in Immunopathology

Volumn 35, Issue 1, 2013, Pages 39-52

  Raimondo, Giovanni ^a   Caccamo, Gaia ^a   Filomia, Roberto ^a   Pollicino, Teresa ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

HBV cccDNA; HBV oncogenecity; HBV replication and gene expression; HBV transmission; HBV related liver disease; Hepatitis B virus (HBV); Occult HBV infection (OBI)

Indexed keywords

HEPATITIS B SURFACE ANTIGEN;

BLOOD TRANSFUSION; BONE MARROW TRANSPLANTATION; EPIGENETICS; HEART TRANSPLANTATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MIXED INFECTION; PREVALENCE; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; VIROLOGY; VIRUS GENOME; VIRUS INHIBITION; VIRUS REPLICATION;

CARCINOMA, HEPATOCELLULAR; DNA, VIRAL; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; LIVER; LIVER NEOPLASMS; VIRUS REPLICATION;

EID: 84872417413     PISSN: 18632297     EISSN: 18632300     Source Type: Journal    
DOI: 10.1007/s00281-012-0327-7     Document Type: Review

References (100)

1. (2009). EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 50:227-242
2. Raimondo G, Allain JP, Brunetto MR, Buendia MA, Chen DS, Colombo M, Craxi A, Donato F, Ferrari C, Gaeta GB, Gerlich WH, Levrero M, Locarnini S, Michalak T, Mondelli MU, Pawlotsky JM, Pollicino T, Prati D, Puoti M, Samuel D, Shouval D, Smedile A, Squadrito G, Trepo C, Villa E, Will H, Zanetti AR, Zoulim F (2008) Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 49:652-657
3. Cacciola I, Pollicino T, Squadrito G, Cerenzia G, Orlando ME, Raimondo G (1999) Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med 341:22-26
4. Wands JR, Chura CM, Roll FJ, Maddrey WC (1975) Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders. Gastroenterology 68:105-112
5. Torbenson M, Thomas DL (2002) Occult hepatitis B. Lancet Infect Dis 2:479-486
6. Thiers V, Nakajima E, Kremsdorf D, Mack D, Schellekens H, Driss F, Goudeau A, Wands J, Sninsky J, Tiollais P (1988) Transmission of hepatitis B from hepatitis-B-seronegative subjects. Lancet 2:1273-1276
7. Shafritz DA, Shouval D, Sherman HI, Hadziyannis SJ, Kew MC (1981) Integration of hepatitis B virus DNA into the genome of liver cells in chronic liver disease and hepatocellular carcinoma. Studies in percutaneous liver biopsies and post-mortem tissue specimens. N Engl J Med 305:1067-1073
8. Rehermann B, Ferrari C, Pasquinelli C, Chisari FV (1996) The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 2:1104-1108
9. Pollicino T, Squadrito G, Cerenzia G, Cacciola I, Raffa G, Craxi A, Farinati F, Missale G, Smedile A, Tiribelli C, Villa E, Raimondo G (2004) Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterology 126:102-110
10. Penna A, Artini M, Cavalli A, Levrero M, Bertoletti A, Pilli M, Chisari FV, Rehermann B, Del PG, Fiaccadori F, Ferrari C (1996) Long-lasting memory T cell responses following self-limited acute hepatitis B. J Clin Invest 98:1185-1194
11. Michalak TI, Pasquinelli C, Guilhot S, Chisari FV (1994) Hepatitis B virus persistence after recovery from acute viral hepatitis. J Clin Invest 94:907
12. Kaneko S, Miller RH, Feinstone SM, Unoura M, Kobayashi K, Hattori N, Purcell RH (1989) Detection of serum hepatitis B virus DNA in patients with chronic hepatitis using the polymerase chain reaction assay. Proc Natl Acad Sci USA 86:312-316
13. Hoofnagle JH, Seeff LB, Bales ZB, Zimmerman HJ (1978) Type B hepatitis after transfusion with blood containing antibody to hepatitis B core antigen. N Engl J Med 298:1379-1383
14. Chazouilleres O, Mamish D, Kim M, Carey K, Ferrell L, Roberts JP, Ascher NL, Wright TL (1994) "Occult" hepatitis B virus as source of infection in liver transplant recipients. Lancet 343:142-146
15. Brechot C, Hadchouel M, Scotto J, Fonck M, Potet F, Vyas GN, Tiollais P (1981) State of hepatitis B virus DNA in hepatocytes of patients with hepatitis B surface antigen-positive and -negative liver diseases. Proc Natl Acad Sci USA 78:3906-3910
16. Pollicino T, Saitta C, Raimondo G (2011) Hepatocellular carcinoma: the point of view of the hepatitis B virus. Carcinogenesis 32:1122-1132
17. Ganem D, Prince AM (2004) Hepatitis B virus infection - natural history and clinical consequences. N Engl J Med 350:1118-1129
18. Levrero M, Pollicino T, Petersen J, Belloni L, Raimondo G, Dandri M (2009) Control of cccDNA function in hepatitis B virus infection. J Hepatol 51:581-592
19. Zoulim F (2005) New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. J Hepatol 42:302-308
20. Raimondo G, Pollicino T, Cacciola I, Squadrito G (2007) Occult hepatitis B virus infection. J Hepatol 46:160-170
21. Pollicino T, Raffa G, Costantino L, Lisa A, Campello C, Squadrito G, Levrero M, Raimondo G (2007) Molecular and functional analysis of occult hepatitis B virus isolates from patients with hepatocellular carcinoma. Hepatology 45:277-285
22. Mulrooney-Cousins PM, Michalak TI (2007) Persistent occult hepatitis B virus infection: experimental findings and clinical implications. World J Gastroenterol 13:5682-5686
23. Wong DK, Huang FY, Lai CL, Poon RT, Seto WK, Fung J, Hung IF, Yuen MF (2011) Occult hepatitis B infection and HBV replicative activity in patients with cryptogenic cause of hepatocellular carcinoma. Hepatology 54:829-836
24. Mason AL, Xu L, Guo L, Kuhns M, Perrillo RP (1998) Molecular basis for persistent hepatitis B virus infection in the liver after clearance of serum hepatitis B surface antigen. Hepatology 27:1736-1742
25. Zerbini A, Pilli M, Boni C, Fisicaro P, Penna A, Di VP, Giuberti T, Orlandini A, Raffa G, Pollicino T, Raimondo G, Ferrari C, Missale G (2008) The characteristics of the cell-mediated immune response identify different profiles of occult hepatitis B virus infection. Gastroenterology 134:1470-1481
26. Bes M, Vargas V, Piron M, Casamitjana N, Esteban JI, Vilanova N, Pinacho A, Quer J, Puig L, Guardia J, Sauleda S (2011) T cell responses and viral variability in blood donation candidates with occult hepatitis B infection. J Hepatol
27. Cohen Stuart JW, Velema M, Schuurman R, Boucher CA, Hoepelman AI (2009) Occult hepatitis B in persons infected with HIV is associated with low CD4 counts and resolves during antiretroviral therapy. J Med Virol 81:441-445
28. Martin CM, Welge JA, Shire NJ, Shata MT, Sherman KE, Blackard JT (2009) Cytokine expression during chronic versus occult hepatitis B virus infection in HIV co-infected individuals. Cytokine 47:194-198
29. Guidotti LG, Chisari FV (2001) Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol 19:65-91
30. Lucifora J, Durantel D, Testoni B, Hantz O, Levrero M, Zoulim F (2010) Control of hepatitis B virus replication by innate response of HepaRG cells. Hepatology 51:63-72
31. Lieberman PM (2008) Chromatin organization and virus gene expression. J Cell Physiol 216:295-302
32. Takacs M, Banati F, Koroknai A, Segesdi J, Salamon D, Wolf H, Niller HH, Minarovits J (2010) Epigenetic regulation of latent Epstein-Barr virus promoters. Biochim Biophys Acta 1799:228-235
33. Bloom DC, Giordani NV, Kwiatkowski DL (2010) Epigenetic regulation of latent HSV-1 gene expression. Biochim Biophys Acta 1799:246-256
34. Pollicino T, Belloni L, Raffa G, Pediconi N, Squadrito G, Raimondo G, Levrero M (2006) Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones. Gastroenterology 130:823-837
35. Werle-Lapostolle B, Bowden S, Locarnini S, Wursthorn K, Petersen J, Lau G, Trepo C, Marcellin P, Goodman Z, Delaney WE, Xiong S, Brosgart CL, Chen SS, Gibbs CS, Zoulim F (2004) Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 126:1750-1758
36. Cougot D, Allemand E, Riviere L, Benhenda S, Duroure K, Levillayer F, Muchardt C, Buendia MA, Neuveut C (2012) Inhibition of PP1 phosphatase activity by HBx: A mechanism for the activation of hepatitis B virus transcription. Sci Signal 5, ra1
37. Belloni L, Pollicino T, De NF, Guerrieri F, Raffa G, Fanciulli M, Raimondo G, Levrero M (2009) Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function. Proc Natl Acad Sci USA 106:19975-19979
38. Klass CM, Krug LT, Pozharskaya VP, Offermann MK (2005) The targeting of primary effusion lymphoma cells for apoptosis by inducing lytic replication of human herpesvirus 8 while blocking virus production. Blood 105:4028-4034
39. Feng WH, Kenney SC (2006) Valproic acid enhances the efficacy of chemotherapy in EBV-positive tumors by increasing lytic viral gene expression. Cancer Res 66:8762-8769
40. Grewal J, Dellinger CA, Yung WK (2007) Fatal reactivation of hepatitis B with temozolomide. N Engl J Med 356:1591-1592
41. Belloni L, Allweiss L, Guerrieri F, Pediconi N, Volz T, Pollicino T, Petersen J, Raimondo G, Dandri M, Levrero M (2012) IFN-á inhibits HBV transcription and replication by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. J Clin Invest In Press
42. Vivekanandan P, Thomas D, Torbenson M (2009) Methylation regulates hepatitis B viral protein expression. J Infect Dis 199:1286-1291
43. Kaur P, Paliwal A, Durantel D, Hainaut P, Scoazec JY, Zoulim F, Chemin I, Herceg Z (2010) DNA methylation of hepatitis B virus (HBV) genome associated with the development of hepatocellular carcinoma and occult HBV infection. J Infect Dis 202:700-704
44. El CM, Candotti D, Crowther RA, Allain JP (2010) Impact of hepatitis B virus surface protein mutations on the diagnosis of occult hepatitis B virus infection. Hepatology 52:1600-1610
45. Vivekanandan P, Kannangai R, Ray SC, Thomas DL, Torbenson M (2008) Comprehensive genetic and epigenetic analysis of occult hepatitis B from liver tissue samples. Clin Infect Dis 46:1227-1236
46. Pollicino T, Amaddeo G, Restuccia A, Raffa, G, Alibrandi A, Cutroneo G, Favaloro A, Maimone, S, Squadrito G, Raimondo G (2012) Impact of hepatitis B virus (HBV) preS/S genomic variability on HBV surface antigen and HBV DNA serum levels. Hepatology In Press
47. Raimondo G, Cacciamo G, Saitta C (2005) Hepatitis B virus and hepatitis C virus co-infection: additive players in chronic liver disease? Ann Hepatol 4:100-106
48. Bellecave P, Gouttenoire J, Gajer M, Brass V, Koutsoudakis G, Blum HE, Bartenschlager R, Nassal M, Moradpour D (2009) Hepatitis B and C virus coinfection: a novel model system reveals the absence of direct viral interference. Hepatology 50:46-55
49. McClary H, Koch R, Chisari FV, Guidotti LG (2000) Inhibition of hepatitis B virus replication during schistosoma mansoni infection in transgenic mice. J Exp Med 192:289-294
50. Hollinger FB (2008) Hepatitis B virus infection and transfusion medicine: science and the occult. Transfusion 48:1001-1026
51. Candotti D, Allain JP (2009) Transfusion-transmitted hepatitis B virus infection. J Hepatol 51:798-809
52. Shetty K, Hussain M, Nei L, Reddy KR, Lok AS (2008) Prevalence and significance of occult hepatitis B in a liver transplant population with chronic hepatitis C. Liver Transpl 14:534-540
53. Shouval D (2008) What is the clinical significance of the high prevalence of occult hepatitis B in US liver transplant patients with chronic hepatitis C? Liver Transpl 14:418-419
54. Georgiadou SP, Zachou K, Liaskos C, Gabeta S, Rigopoulou EI, Dalekos GN (2009) Occult hepatitis B virus infection in patients with autoimmune liver diseases. Liver Int 29:434-442
55. Torbenson M, Kannangai R, Astemborski J, Strathdee SA, Vlahov D, Thomas DL (2004) High prevalence of occult hepatitis B in Baltimore injection drug users. Hepatology 39:51-57
56. Toyoda H, Hayashi K, Murakami Y, Honda T, Katano Y, Nakano I, Goto H, Kumada T, Takamatsu J (2004) Prevalence and clinical implications of occult hepatitis B viral infection in hemophilia patients in Japan. J Med Virol 73:195-199
57. Yakaryilmaz F, Gurbuz OA, Guliter S, Mert A, Songur Y, Karakan T, Keles H (2006) Prevalence of occult hepatitis B and hepatitis C virus infections in Turkish hemodialysis patients. Ren Fail 28:729-735
58. Sav T, Gursoy S, Torun E, Sav NM, Unal A, Oymak O, Utas C (2010) Occult HBV infection in continuous ambulatory peritoneal dialysis and hemodialysis patients. Ren Fail 32:74-77
59. Fabrizi F, Messa PG, Lunghi G, Aucella F, Bisegna S, Mangano S, Villa M, Barbisoni F, Rusconi E, Martin P (2005) Occult hepatitis B virus infection in dialysis patients: a multicentre survey. Aliment Pharmacol Ther 21:1341-1347
60. Di SM, Volpe A, Stallone G, Tartaglia L, Prato R, Martinelli D, Pastore G, Gesualdo L, Fiore JR (2009) Occult HBV infection in hemodialysis setting is marked by presence of isolated antibodies to HBcAg and HCV. J Nephrol 22:381-386
61. Raffa G, Maimone S, Cargnel A, Santantonio T, Antonucci G, Massari M, Schiavini M, Caccamo G, Pollicino T, Raimondo G (2007) Analysis of occult hepatitis B virus infection in liver tissue of HIV patients with chronic hepatitis C. AIDS 21:2171-2175
62. Minuk GY, Sun DF, Uhanova J, Zhang M, Caouette S, Nicolle LE, Gutkin A, Doucette K, Martin B, Giulivi A (2005) Occult hepatitis B virus infection in a North American community-based population. J Hepatol 42:480-485
63. Kim SM, Lee KS, Park CJ, Lee JY, Kim KH, Park JY, Lee JH, Kim HY, Yoo JY, Jang MK (2007) Prevalence of occult HBV infection among subjects with normal serum ALT levels in Korea. J Infect 54:185-191
64. Hui CK, Sun J, Au WY, Lie AK, Yueng YH, Zhang HY, Lee NP, Hou JL, Liang R, Lau GK (2005) Occult hepatitis B virus infection in hematopoietic stem cell donors in a hepatitis B virus endemic area. J Hepatol 42:813-819
65. Raimondo G, Navarra G, Mondello S, Costantino L, Colloredo G, Cucinotta E, Di VG, Scisca C, Squadrito G, Pollicino T (2008) Occult hepatitis B virus in liver tissue of individuals without hepatic disease. J Hepatol 48:743-746
66. Stramer SL, Wend U, Candotti D, Foster GA, Hollinger FB, Dodd RY, Allain JP, Gerlich W (2011) Nucleic acid testing to detect HBV infection in blood donors. N Engl J Med 364:236-247
67. Hollinger FB, Sood G (2010) Occult hepatitis B virus infection: a covert operation. J Viral Hepat 17:1-15
68. Allain JP, Cox L (2011) Challenges in hepatitis B detection among blood donors. Curr Opin Hematol 18:461-466
69. Belloni L (1972) Morgagni-Reaumur correspondence in the Public Library of Forli. Gesnerus 29:225-254
70. Kannangai R, Vivekanandan P, Netski D, Mehta S, Kirk GD, Thomas DL, Torbenson M (2007) Liver enzyme flares and occult hepatitis B in persons with chronic hepatitis C infection. J Clin Virol 39:101-105
71. Chemin I, Guillaud O, Queyron PC, Trepo C (2009) Close monitoring of serum HBV DNA levels and liver enzymes levels is most useful in the management of patients with occult HBV infection. J Hepatol 51:824-825
72. Komiya Y, Katayama K, Yugi H, Mizui M, Matsukura H, Tomoguri T, Miyakawa Y, Tabuchi A, Tanaka J, Yoshizawa H (2008) Minimum infectious dose of hepatitis B virus in chimpanzees and difference in the dynamics of viremia between genotype A and genotype C. Transfusion 48:286-294
73. Allain JP, Belkhiri D, Vermeulen M, Crookes R, Cable R, Amiri A, Reddy R, Bird A, Candotti D (2009) Characterization of occult hepatitis B virus strains in South African blood donors. Hepatology 49:1868-1876
74. Cheung CK, Lo CM, Man K, Lau GK (2010) Occult hepatitis B virus infection of donor and recipient origin after liver transplantation despite nucleoside analogue prophylaxis. Liver Transpl 16:1314-1323
75. Cholongitas E, Papatheodoridis GV, Burroughs AK (2010) Liver grafts from anti-hepatitis B core positive donors: a systematic review. J Hepatol 52:272-279
76. Coffin CS, Mulrooney-Cousins PM, van MG, Roberts JP, Michalak TI, Terrault NA (2011) Hepatitis B virus quasispecies in hepatic and extrahepatic viral reservoirs in liver transplant recipients on prophylactic therapy. Liver Transpl 17:955-962
77. Toniutto P, Minisini R, Fabris C, De FT, Marangoni F, Burlone M, Avellini C, Bitetto D, Fornasiere E, Fumolo E, Baccarani U, Pirisi M (2009) Occult hepatitis B virus infection in liver transplant recipients with recurrent hepatitis C: relationship with donor age and fibrosis progression. Clin Transplant 23:184-190
78. Kusumoto S, Tanaka Y, Mizokami M, Ueda R (2009) Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma. Int J Hematol 90:13-23
79. Lalazar G, Rund D, Shouval D (2007) Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol 136:699-712
80. Loomba R, Rowley A, Wesley R, Liang TJ, Hoofnagle JH, Pucino F, Csako G (2008) Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 148:519-528
81. Marzano A, Angelucci E, Andreone P, Brunetto M, Bruno R, Burra P, Caraceni P, Daniele B, Di Marco V, Fabrizi F, Fagiuoli S, Grossi P, Lampertico P, Meliconi R, Mangia A, Puoti M, Raimondo G, Smedile A (2007) Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis 39:397-408
82. Ritchie D, Piekarz RL, Blombery P, Karai LJ, Pittaluga S, Jaffe ES, Raffeld M, Janik JE, Prince HM, Bates SE (2009) Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: a case series report. Haematologica 94:1618-1622
83. Pei SN, Chen CH, Lee CM, Wang MC, Ma MC, Hu TH, Kuo CY (2010) Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients. Ann Hematol 89:255-262
84. Yeo W, Chan TC, Leung NW, Lam WY, Mo FK, Chu MT, Chan HL, Hui EP, Lei KI, Mok TS, Chan PK (2009) Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 27:605-611
85. Onozawa M, Hashino S, Izumiyama K, Kahata K, Chuma M, Mori A, Kondo T, Toyoshima N, Ota S, Kobayashi S, Hige S, Toubai T, Tanaka J, Imamura M, Asaka M (2005) Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogeneic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection. Transplantation 79:616-619
86. Vigano M, Vener C, Lampertico P, Annaloro C, Pichoud C, Zoulim F, Facchetti F, Poli F, Scalamogna M, Deliliers GL, Colombo M (2011) Risk of hepatitis B surface antigen seroreversion after allogeneic hematopoietic SCT. Bone Marrow Transplant 46:125-131
87. Coppola N, Tonziello G, Pisaturo M, Messina V, Guastafierro S, Fiore M, Iodice V, Sagnelli C, Stanzione M, Capoluongo N, Pasquale G, Sagnelli E (2011) Reactivation of overt and occult hepatitis B infection in various immunosuppressive settings. J Med Virol 83:1909-1916
88. Sanchez MJ, Buti M, Homs M, Palacios A, Rodriguez-Frias F, Esteban R (2009) Successful use of entecavir for a severe case of reactivation of hepatitis B virus following polychemotherapy containing rituximab. J Hepatol 51:1091-1096
89. Blackberg J, Kidd-Ljunggren K (2000) Occult hepatitis B virus after acute self-limited infection persisting for 30 years without sequence variation. J Hepatol 33:992-997
90. Yuki N, Nagaoka T, Yamashiro M, Mochizuki K, Kaneko A, Yamamoto K, Omura M, Hikiji K, Kato M (2003) Long-term histologic and virologic outcomes of acute self-limited hepatitis B. Hepatology 37:1172-1179
91. Raimondo G, Pollicino T, Squadrito G (2005) What is the clinical impact of occult hepatitis B virus infection? Lancet 365:638-640
92. Brechot C (2004) Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms. Gastroenterology 127:S56-S61
93. Shi Y, Wu YH, Wu W, Zhang WJ, Yang J, Chen Z (2012) Association between occult hepatitis B infection and the risk of hepatocellular carcinoma: a meta-analysis. Liver Int 32:231-240
94. Corradini E, Ferrara F, Pollicino T, Vegetti A, Abbati GL, Losi L, Raimondo G, Pietrangelo A (2007) Disease progression and liver cancer in the ferroportin disease. Gut 56:1030-1032
95. Fwu CW, Chien YC, Kirk GD, Nelson KE, You SL, Kuo HS, Feinleib M, Chen CJ (2009) Hepatitis B virus infection and hepatocellular carcinoma among parous Taiwanese women: nationwide cohort study. J Natl Cancer Inst 101:1019-1027
96. Fwu CW, Chien YC, You SL, Nelson KE, Kirk GD, Kuo HS, Feinleib M, Chen CJ (2011) Hepatitis B virus infection and risk of intrahepatic cholangiocarcinoma and non-Hodgkin lymphoma: a cohort study of parous women in Taiwan. Hepatology 53:1217-1225
97. Marcucci F, Mele A, Spada E, Candido A, Bianco E, Pulsoni A, Chionne P, Madonna E, Cotichini R, Barbui A, De RA, Dore F, Iannitto E, Liso V, Martino B, Montanaro M, Pagano L, Musto P, Rapicetta M (2006) High prevalence of hepatitis B virus infection in B-cell non-Hodgkin's lymphoma. Haematologica 91:554-557
98. Tanaka M, Tanaka H, Tsukuma H, Ioka A, Oshima A, Nakahara T (2010) Risk factors for intrahepatic cholangiocarcinoma: a possible role of hepatitis B virus. J Viral Hepat 17:742-748
99. Perumal V, Wang J, Thuluvath P, Choti M, Torbenson M (2006) Hepatitis C and hepatitis B nucleic acids are present in intrahepatic cholangiocarcinomas from the United States. Hum Pathol 37:1211-1216
100. Rossi D, Sala L, Minisini R, Fabris C, Falleti E, Cerri M, Burlone ME, Toniutto P, Gaidano G, Pirisi M (2009) Occult hepatitis B virus infection of peripheral blood mononuclear cells among treatment-naive patients with chronic lymphocytic leukemia. Leuk Lymphoma 50:604-611